Posters and Presentations :: SCYNEXIS, Inc. (SCYX)

$Oral Ibrexafungerp (SCY-078) in Refractory Fungal Diseases<br><sup>Interim Analysis by Pathogen of a Phase 3 Open-label Study (FURI)</sup>$

Oral Ibrexafungerp (SCY-078) in Refractory Fungal Diseases
^{Interim Analysis by Pathogen of a Phase 3 Open-label Study (FURI)}

Oliver A. Cornely MD, FECMM, FIDSA, FAAM, FACP
Consultant, Infectious Diseases
Director, European Mycology Excellence Center
University Hospital of Cologne
ECCMID 2019

Successful Treatment of Two Patients with <em>Candida auris</em> Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078), from the CARES Study

Successful Treatment of Two Patients with Candida auris Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078), from the CARES Study

D Juneja, O Singh, B Tarai, DA Angulo
ECCMID 2019
April 2019

Favourable Clinical Outcome of Two Patients with <em>Candida</em> spp. Spondylodiscitis treated with Oral Ibrexafungerp (formerly SCY-078) from the FURI Study

Favourable Clinical Outcome of Two Patients with Candida spp. Spondylodiscitis treated with Oral Ibrexafungerp (formerly SCY-078) from the FURI Study

Philipp Koehler, Oliver A. Cornerly, David Angulo
ECCMID 2019
April 2019

$Use of Ibrexafungerp (formerly SCY-078) to Treat Severe Azole Refractory Esophageal Candidiasis. A Case Report from the Furi Study$

Use of Ibrexafungerp (formerly SCY-078) to Treat Severe Azole Refractory Esophageal Candidiasis. A Case Report from the Furi Study

J Vazquez, Aprile Osborn, D Angulo
ECCMID 2019
April 2019

Penetration of Ibrexafungerp (formerly SCY-078) versus Micafungin at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model

Annie Lee, Brendan Prideaux, Min Hee Lee, Matthew Zimmerman, Padmaja Paderu, Stephen A. Barat, David Angulo, David S. Perlin, Yanan Zhao
ECCMID 2019
April 2019